Tzu Chi Medical Journal最新文献

{"title":"The updated network meta-analysis of the therapeutic efficacies of lung cancer: A systematic review and meta-analysis.","authors":"Chuan-Hsin Chang, Chih-Cheng Chien, Yue-Cune Chang","doi":"10.4103/tcmj.tcmj_264_24","DOIUrl":"10.4103/tcmj.tcmj_264_24","url":null,"abstract":"<p><strong>Objectives: </strong>Lung cancer is one of the most common malignancies worldwide. We aim to investigate the most effective treatments for advanced/nonadvanced stages of lung cancer patients.</p><p><strong>Materials and methods: </strong>We searched electronic databases to investigate the treatment efficacies of lung cancer. The network meta-analysis was used to identify the top five most effective therapeutic strategies. A total of 157 studies were collected with a cumulative total of 164,678 participants.</p><p><strong>Results: </strong>The results showed that the best top five treatments: (1) for advanced lung cancer in response rate, were Chemo + Chemotherapy + Targeted Therapy, Cell therapy + Immunotherapy, Targeted Therapy + Radiotherapy, Chemoradiotherapy + Immunotherapy, and Chemotherapy + Chemoradiotherapy with cumulative probabilities 50.5, 49.6, 47.7, 46.0, and 45.6%; (2) for advanced lung cancer in progression-free survival (PFS) rate, were Targeted + Radiotherapy, Targeted + Others Therapy, Targeted + Targeted Therapy, Immu + Immu + Chemo Therapy, and Chemoradiotherapy with cumulative probabilities 99.5, 82.8, 44.9, 36.5, and 33.6%; (3) for nonadvanced lung cancer in response rate, were Chemoradiotherapy + Immu, Chemoradiotherapy + Targeted therapy, Chemoradiotherapy + Others, Chemotherapy + Surgery, and Radiotherapy + Others with cumulative probabilities 79.1, 74.9, 66.9, 60.4, and 54.2%; (4) for non-advanced lung cancer in PFS rate, were Chemo + Surgery, Chemoradiotherapy + Targeted, Surgery, Surgery + Radiotherapy, and Chemoradiotherapy + Others with cumulative probabilities 88.3, 86.1, 78.3, 73.1, and 50.8%.</p><p><strong>Conclusion: </strong>We present the latest and most effective therapeutic strategies for patients with advanced or nonadvanced stages of lung cancer.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"37 3","pages":"339-347"},"PeriodicalIF":1.6,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exosomal long noncoding RNAs and microRNAs in colorectal cancer.","authors":"Yun Yen, Tang-Yuan Chu, Ruo-Chia Tseng","doi":"10.4103/tcmj.tcmj_62_25","DOIUrl":"10.4103/tcmj.tcmj_62_25","url":null,"abstract":"<p><p>This review focuses on the multifaceted roles of exosomal noncoding RNAs (ncRNAs) in colorectal cancer (CRC), utilizing the provided document as the primary source of information. Exosomes, nanoscale vesicles ranging from 30 to 150 nm, act as crucial mediators of intercellular communication, encapsulating bioactive molecules such as microRNAs (miRNAs) and long ncRNAs (lncRNAs). The biogenesis of exosomes involves the endocytic pathway, including the formation of multivesicular bodies and subsequent release of intraluminal vesicles into the extracellular space. This process is regulated by the endosomal sorting complex required for transport (ESCRT) machinery and other ESCRT-independent mechanisms, as well as RNA-binding proteins (RBPs) that selectively package ncRNAs. MiRNAs, shorter single-stranded RNA molecules, regulate gene expression post-transcriptionally by binding to target mRNAs, leading to translational repression or mRNA degradation. LncRNAs, longer RNA molecules, are involved in chromatin remodeling and transcriptional regulation and act as competing endogenous RNAs that modulate miRNA availability. Exosomal ncRNAs play a crucial role in tumorigenesis, where certain miRNAs promote proliferation while others act as tumor suppressors. Furthermore, these ncRNAs are central to the epithelial-mesenchymal transition, a critical process that facilitates metastasis. They also play a role in chemoresistance by modulating drug metabolism and apoptotic pathways. Exosomal ncRNAs also show promise as diagnostic and prognostic biomarkers due to their presence in body fluids and their association with disease progression. Moreover, they hold potential as therapeutic agents through RNA-based therapeutics and exosome-based drug delivery. The challenges involve standardizing exosome research, elucidating the underlying mechanisms, and ensuring successful clinical translation.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"37 3","pages":"235-246"},"PeriodicalIF":1.6,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term cardiovascular outcomes after exercise-based cardiac rehabilitation among coronavirus disease 2019 survivors: A nationwide cohort study.","authors":"Jing-Wun Lu, Sheng-Hsiang Ma, Wei-Fan Ou, Hsin-Hua Chen, Tai-Li Chen, Chung-Chao Liang","doi":"10.4103/tcmj.tcmj_154_24","DOIUrl":"10.4103/tcmj.tcmj_154_24","url":null,"abstract":"<p><strong>Objectives: </strong>Coronavirus disease 2019 (COVID-19) is associated with poor cardiac outcomes and an increased risk of long-term cardiovascular disease. Long-term cardiovascular outcomes among patients with COVID-19 after exercise-based cardiac rehabilitation remain largely unknown. This study aimed to investigate the long-term cardiovascular outcomes of COVID-19 survivors after exercise-based cardiac rehabilitation using real-world data.</p><p><strong>Materials and methods: </strong>We analyzed the data from the US Collaborative Network of the TriNetX Research Database. Adults aged ≥18 years who were diagnosed with COVID-19 between 2020 and 2022 were enrolled in this study. The comparison comprised a cohort of patients receiving exercise-based cardiac rehabilitation and 1:1 propensity score-matched controls.</p><p><strong>Results: </strong>The exercise-based cardiac rehabilitation group was found to have lower risks of developing several long-term cardiovascular outcomes than the controls, such as mortality (hazard ratio [HR] = 0.75 [0.63-0.89]), stroke (HR = 0.81 [0.68-0.94]), myocardial infarction (HR = 0.75 [0.61-0.89]), ischemic cardiomyopathy (HR = 0.86 [0.75-0.99]), heart failure (HR = 0.73 [0.65-0.83]), and nonischemic cardiomyopathy (HR = 0.78 [0.63-0.92]).</p><p><strong>Conclusion: </strong>Among COVID-19 survivors, those undergoing cardiac rehabilitation had lower risks of cardiovascular outcomes, including mortality, stroke, myocardial infarction, ischemic cardiomyopathy, heart failure, and nonischemic cardiomyopathy, than those of controls.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"37 3","pages":"293-298"},"PeriodicalIF":1.6,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacterial co-infection and secondary infection in critically ill patients with acute respiratory failure of coronavirus disease 2019.","authors":"Yi-Ting Chen, Ya-Ju Wu, Li-Liang Chuang, Hui-Sheng Wang, Yuan-Chieh Chang","doi":"10.4103/tcmj.tcmj_255_24","DOIUrl":"10.4103/tcmj.tcmj_255_24","url":null,"abstract":"<p><strong>Objectives: </strong>The objective of the study is to understand the prevalence of bacterial co-infection and secondary infection in severe coronavirus disease 2019 (COVID-19) pneumonia in a tertiary hospital intensive care unit (ICU), the spectrum of pathogens, and the impact of these infections on clinical outcomes.</p><p><strong>Materials and methods: </strong>Retrospective analysis of all patients with COVID-19 with acute hypoxemic respiratory failure who were admitted to the ICU requiring invasive mechanical ventilation (IMV) or high-flow nasal cannula (HFNC) from January 2021 to August 2022.</p><p><strong>Results: </strong>Of the 123 cases, 59.3% had culture-confirmed bacterial co-infection, mostly lower respiratory tract infections (LRTIs). Patients with bacterial co-infection had higher 30-day mortality (28.8% vs. 12%, hazard ratio [HR] = 2.96, %95 confidence interval [CI] =1.1-7.99; adjusted HR [aHR] = 1.34, %95 CI = 0.43-4.17). <i>Klebsiella pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa</i> were the most common co-infection pathogens. Of the 108 cases who stayed in the ICU for >2 days, 34 (31.5%) cases developed secondary bacterial infections within 30 days, of whom all cases had LRTI, 4 had bacteremia, and 8 had urinary tract infections. IMV users had a higher 1-month incidence of secondary bacterial infections than HFNC users (47.5% vs. 8.9%, <i>P</i> < 0.0001). Patients with secondary bacterial infections had higher 60-day mortality (32.4% vs. 11.2% HR = 3.45, 95% CI = 1.27-9.4; aHR = 2.29, %95 CI =0.8-6.67). The most common secondary infection pathogens were <i>Acinetobacter</i> species, <i>P</i>. <i>aeruginosa, Stenotrophomonas maltophilia</i>, and <i>K</i>. <i>pneumoniae</i>. At the 30-day follow-up, 54 events of ICU-acquired secondary bacterial LRTI were noted in 34 patients, 18 (33.3%) events, and 15 (44%) patients were infected by carbapenem-resistant Gram-negative bacilli.</p><p><strong>Conclusion: </strong>The high incidence of bacterial co-infection and secondary infection in critically ill patients with COVID-19 might associated with increased mortality. Infection by drug-resistant pathogens may develop during the treatment course.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"37 3","pages":"304-310"},"PeriodicalIF":1.6,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The best pooling strategy to reduce polymerase chain reaction tests during the coronavirus disease-19 pandemic at low prevalence.","authors":"Chen-Lun Chu, Tai-Yin Wu, Sheng-Mou Hou, Kao-Shang Shih, Yo-Lun Chu, Cheng-Kuang Chen, Li-Wei Hung, Hao-Wei Hsu, Chen-Kun Liaw","doi":"10.4103/tcmj.tcmj_244_24","DOIUrl":"10.4103/tcmj.tcmj_244_24","url":null,"abstract":"<p><strong>Objectives: </strong>Pooling can reduce reverse transcriptase polymerase chain reaction (RT-PCR) tests during the coronavirus disease-19 (COVID-19) pandemic. Pooling strategy is a complex issue. Recent advances in computer science may provide a better strategy.</p><p><strong>Materials and methods: </strong>We developed our algorithm which can help healthcare workers set up their pooling policy during the COVID-19 pandemic.</p><p><strong>Results: </strong>Comparing with three other strategies, naming single pooling, array pooling, and hypercube pooling, our multiple pooling shows to be the best with minimal RT-PCR tests per patient.</p><p><strong>Conclusion: </strong>We hope clinicians in COVID-19 pandemic regions can use our algorithm to reduce both RT-PCR tests and time and hence save more lives.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"37 3","pages":"299-303"},"PeriodicalIF":1.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic human umbilical cord blood for acute ischemic stroke: Phase I clinical trial.","authors":"Raymond Y Lo, Yuncin Luo, Shu-Cin Chen, Jen-Hung Wang, Chen-Yu Ko, Ying-Jie Chen, Yu-Chin Su, Tong-Young Lee, Jonas C Wang, Shinn-Zong Lin","doi":"10.4103/tcmj.tcmj_249_24","DOIUrl":"10.4103/tcmj.tcmj_249_24","url":null,"abstract":"<p><strong>Objectives: </strong>Transplantation of human umbilical cord blood cells (hUCB) may enhance neuroprotection, and thus, the intravenous (IV) infusion of hUCB in patients with acute ischemic stroke (AIS) is being tested for its safety and efficacy.</p><p><strong>Materials and methods: </strong>We conducted a 12-month, open-label, and single-center, phase I trial of hUCB treatment in AIS patients at the age of 45-80 years, with magnetic resonance imaging evidence of acute infarction in the internal carotid artery supplied territory and the National Institute of Health Stroke Scale (NIHSS) score between 6 and 18. Eligible participants received a single-dose IV infusion of hUCB followed by the two doses of mannitol infusion within 9 days after the onset of stroke symptoms. The primary endpoint was the incidence of adverse events (AEs) and the secondary endpoints were the changes in NIHSS, Barthel index (BI), and Berg Balance Scale (BBS) scores.</p><p><strong>Results: </strong>Six patients (Male: Female = 3: 3) were enrolled with a mean age at 65.8 years. A total of 40 AEs occurred in six participants during this study, which included nine serious adverse events. Only transient erythema multiforme and hematuria were probably and possibly related to hUCB infusion, respectively. The mean NIHSS score was 11.5 at baseline and it significantly improved at 1, 3, 6, 9, and 12 months after treatment (mean change from baseline: -4.0, -5.3, -6.8, -7.0, and -7.3). The mean BI score was 22.5 at baseline and it significantly increased at 3 and 6 months after treatment (mean change from baseline: 26.7 and 42.5, respectively). The BBS score increased numerically but did not reach statistical significance. The changes in cytokine levels and spleen size were unremarkable.</p><p><strong>Conclusion: </strong>The IV hUCB was safe and well tolerated in AIS patients, and the preliminary efficacy results demonstrated its therapeutic potential, supporting the conduct of a randomized, placebo controlled, phase II clinical trial in future.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"37 3","pages":"321-327"},"PeriodicalIF":1.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic peptides and their delivery using lipid-based nanoparticles.","authors":"Jui-Hung Yen, Chun-Chun Chang, Tien-Yuan Wu, Chin-Hao Yang, Hao-Jen Hsu, Je-Wen Liou","doi":"10.4103/tcmj.tcmj_321_24","DOIUrl":"10.4103/tcmj.tcmj_321_24","url":null,"abstract":"<p><p>Therapeutic peptides have become an intensively anticipated research field for novel drug discovery and design owing to their high specificity, efficacy, and biocompatibility. The advances in computer technology and structural biology, together with the invention of chemical peptide synthesis methods, have led to tremendous progress in this research field. Over the years, more than 100 peptide-based therapeutics have been approved for clinical use, and many others are currently under clinical trials. However, the <i>in vivo</i> application of therapeutic peptides is hindered by intrinsic disadvantages of peptides, such as poor stability against enzymatic degradations, short <i>in vivo</i> half-life, and low oral bioavailability. Therefore, strategies for efficiently protecting the peptides inside the body and facilitating the delivery of peptides to their targets are required. Lipid-based nanoparticles are considered a versatile class of carriers for drug delivery. Their biocompatibility, biodegradability, and ability to interact with biological membranes make them ideal platforms for <i>in vivo</i> delivery of peptides. Here, by leveraging examples, we aim to provide a comprehensive review of the current status of therapeutic peptide developments and lipid-based nanoparticles as drug carriers. Recent attempts to utilize lipid-based nanoparticles as platforms for the oral delivery of therapeutic peptides are also discussed.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"37 3","pages":"223-234"},"PeriodicalIF":1.6,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut-derived uremic toxins and cardiovascular health in chronic kidney disease.","authors":"Ming-Chun Chen, Chiu-Huang Kuo, Yu-Li Lin, Bang-Gee Hsu","doi":"10.4103/tcmj.tcmj_293_24","DOIUrl":"10.4103/tcmj.tcmj_293_24","url":null,"abstract":"<p><p>Uremic toxins (UTs) are bioactive compounds that accumulate in chronic kidney disease (CKD) due to impaired renal clearance, exacerbating disease progression and cardiovascular (CV) complications. These toxins originate from endogenous metabolism, gut microbiota, and dietary intake and include protein-bound UTs such as p-cresyl sulfate, indoxyl sulfate, and indole acetic acid, as well as small, water-soluble toxins such as trimethylamine-N-oxide and phenylacetylglutamine. Their accumulation promotes oxidative stress, inflammation, and endothelial dysfunction, contributing to vascular damage and associated with CV risk. Current management strategies focus on dietary interventions, prebiotics, probiotics, oral sorbents, emerging pharmacological approaches, and advanced dialysis techniques, but clinical outcomes remain inconsistent. Recent trials have demonstrated the potential of agents such as sevelamer, high-amylose-resistant starch, and AST-120 to reduce UT levels and improve certain vascular markers. However, more robust, long-term studies are necessary to fully establish the therapeutic efficacy and optimize treatment strategies to mitigate the impact of gut-derived UTs on CKD and CV health.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"37 3","pages":"264-274"},"PeriodicalIF":1.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comprehensive review of surgical techniques for chronic Achilles tendon rupture.","authors":"Kuang-Ting Yeh, Wen-Tien Wu, Chia-Ming Chang, Tzai-Chiu Yu, Ing-Ho Chen, Chen-Chie Wang","doi":"10.4103/tcmj.tcmj_250_24","DOIUrl":"10.4103/tcmj.tcmj_250_24","url":null,"abstract":"<p><p>Chronic Achilles tendon rupture (CATR) represents a significant clinical challenge, often necessitating surgical intervention to restore function, alleviate pain, and prevent long-term complications. The complex nature of CATR, characterized by tendon retraction, scar formation, and poor tissue quality, requires a tailored, evidence-based approach. This review comprehensively examines current surgical strategies for managing CATR, focusing on their indications, advantages, outcomes, and associated complications. A detailed literature search of 20 studies published between 2010 and 2023 identified key surgical techniques, including end-to-end repair, tendon transfers, autografts, synthetic grafts, and allografts. Surgical recommendations were stratified by defect size and patient factors. Small defects (<2 cm) are effectively managed with end-to-end repair or tendon transfers, offering rapid recovery and restoration of tendon continuity. Medium defects (2-5 cm) benefit from techniques such as V-Y plasty or semitendinosus autografts, providing additional length and biomechanical stability. Larger defects (>5 cm) often necessitate advanced procedures, including free tendon grafts, synthetic materials, or allografts, particularly for older patients or those with poor tissue quality. Minimally invasive techniques, such as endoscopic flexor hallucis longus transfer, have shown promise in reducing recovery times and complications. A structured decision-making framework is proposed to guide surgical choices, ensuring patient-specific, optimal outcomes. Emerging techniques further expand the possibilities for managing this challenging condition, emphasizing the need for innovation and individualized care in CATR treatment.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"37 3","pages":"247-254"},"PeriodicalIF":1.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reciprocal regulation between B lymphoma Mo-MLV insertion region 1 homolog and type I insulin-like growth factor receptor in pemetrexed-resistant lung cancer cells.","authors":"Huan-Ting Shen, Peng-Ju Chien, Gwo-Tarng Sheu, Bing-Yen Wang, Wen-Wei Chang","doi":"10.4103/tcmj.tcmj_288_24","DOIUrl":"10.4103/tcmj.tcmj_288_24","url":null,"abstract":"<p><strong>Objectives: </strong>The objective of this study was to investigate the role of type I insulin-like growth factor receptor (IGF-1R) in pemetrexed-resistant lung cancer cells and its interaction with B lymphoma Mo-MLV insertion region 1 homolog (BMI1), previously identified as a key resistance gene.</p><p><strong>Materials and methods: </strong>The study started with the analysis of the activation of IGF-1R in pemetrexed-resistant A549 (A400) lung cancer cells by Western blot analysis of its form of phosphorylation. Cancer stem cell (CSC) activity was assessed by tumor sphere culture. IGF-1R inhibition was performed by picropodophyllin (PPP), an IGF-1R inhibitor, or by shRNA-mediated RNA silencing. A Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse xenograft model was used to access <i>in vivo</i> pemetrexed sensitivity. To further understand the relationship between IGF-1R and BMI1, both BMI1 knockdown and overexpression experiments were performed to assess IGF-1R phosphorylation by western blot.</p><p><strong>Results: </strong>Increased IGF-1R phosphorylation was found in A400 cells, and subsequent IGF-1R inhibition resulted in a reduction in CSC activity in these resistant cells. In the <i>in vivo</i> studies, PPP treatment effectively suppressed tumor growth and reduced BMI1 expression in A400 tumor tissue. Further investigation showed that BMI1 knockdown in A400 cells resulted in decreased IGF-1R phosphorylation, whereas BMI1 overexpression in A549 cells resulted in increased IGF-1R phosphorylation, indicating an interaction between these two proteins.</p><p><strong>Conclusion: </strong>A novel reciprocal regulatory relationship between IGF-1R and BMI1 has been identified in lung cancer cells, suggesting potential therapeutic strategies to combat pemetrexed resistance in lung cancer patients.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"37 3","pages":"285-292"},"PeriodicalIF":1.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}